Ariad Pharmaceuticals, Inc. (ARIA) To Seek Regulatory Clearance For Brigatinib In 3Q
Published on June 8, 2016 at 5:25 pm
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) has said that it will file a new drug application (NDA) for its pipeline candidate brigatinib in 3Q2016. This followed a presentation of pivotal Phase 2 data for the compound at the ASCO conference. According to Ariad, brigatinib showed impressive results in ALK+ lung cancer patients who received it during the study. Those patients had experienced a progression of their disease condition even after receiving Pfizer Inc. (NYSE:PFE) drug Xalkori.
Ariad said that it has already initiated a Phase 3 study of brigatinib that will focus primarily on evaluating the efficacy of the compound against Xalkori from Pfizer.
Ariad Drug Appears To Delay Lung Cancer's Return Longer Than Rival Medicines
Ariad Pharmaceuticals’ experimental drug to treat patients with non-small cell lung cancer who’ve stopped benefiting from Pfizer’s Xalkori seems to work longer than other options, and may be better at affecting tumors that have spread to the brain, according to new data to be presented here at the American Society of Clinical Oncology this morning.